Adenosine Shapes Neonatal Toll-like Receptor Function
腺苷塑造新生儿 Toll 样受体功能
基本信息
- 批准号:7630432
- 负责人:
- 金额:$ 36.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-06-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:AdenosineAgonistAnti-Inflammatory AgentsAnti-inflammatoryAntigen-Presenting CellsAntigensBacteriaBiological PreservationBirthCell physiologyCellsComplexCyclic AMPEscherichia coliFrequenciesGoalsHumanHypoxiaImmune responseImmunologic MemoryImpairmentInfectionInflammatoryInterleukin-6MediatingModelingMononuclearNatural ImmunityNatureNeonatalNewborn InfantPhysiologyPlasmaPlayPredispositionProductionPropertyPurine NucleosidesPurinergic P1 ReceptorsPurinesRiskRoleSeveritiesShapesSignal TransductionSignaling MoleculeStimulusStressSystemTLR2 geneTLR4 geneToll-Like Receptor 1Toll-like receptorsTumor Necrosis Factor-alphaUmbilical Cord BloodVaccinationage groupcytokinehuman TNF proteininsightmicrobialmonocytenovel strategiespathogenpathogenic bacteriapreventpurinereceptorreceptor functionresponse
项目摘要
DESCRIPTION (provided by applicant): Newborns are at increased risk of infection yet the mechanisms underlying their susceptibility are incompletely defined. Toll-like receptors (TLRs) play crucial roles in the recognition of microbial components including bacterial lipopeptides (BLPs), expressed by a wide-range of bacteria, that activate monocytes via a heterodimer of TLR1/2 (triacylated BLPs) or TLR2/6 (diacylated BLPs). Preliminary studies indicate that despite normal expression of TLRs and associated signaling components, human newborn blood monocytes demonstrate a 2- to 3-log impairment in BLP-induced synthesis of pro-inflammatory and Th1-polarizing cytokine tumor necrosis factor-alpha (TNF-alpha) with preservation of BLP-induced production of IL-6, a cytokine with anti-inflammatory and Th2-polarizing activities. Similar impairment in neonatal TNF-alpha production is evident in response to E. coli K1/r, a pathogenic bacterium that expresses BLPs. We have discovered that impaired BLP- and E. col1- induced TNF-alpha production from neonatal blood monocytes is attributable to the action of plasma adenosine, an endogenous purine metabolite with immunomodulatory properties that is released from cells under conditions of stress or hypoxia. Neonatal mononuclear cells are especially sensitive to adenosine-induced inhibition of TNF-alpha production and to adenosine-induced production of cyclic AMP, an intracellular metabolite that inhibits TNF-alpha synthesis while preserving IL-6 production. The overall goal of this project is to characterize the role of the neonatal adenosine system in modulating TLR-mediated innate immune responses in neonatal blood monocytes. This goal will be accomplished through three specific aims: (1) to determine the mechanism for the greater adenosine sensitivity of neonatal mononuclear cells, (2) to define the adenosine receptor sub-type(s) that mediate inhibition of BLP- and E. coli-induced TNF-alpha production from neonatal blood monocytes; and (3) to characterize the mechanism by which engagement of adenosine receptors results in diminished BLP- and E. coli-induced monocyte TNF-alpha production while preserving IL-6 production. Mechanistic analysis will define how adenosine alters neonatal TLR-mediated immune responses. As a whole, these studies will deepen our understanding of how the unique physiology of the human newborn fundamentally alters innate immunity at birth.
描述(由申请人提供):新生儿感染的风险增加,但其易感性的机制尚未完全确定。Toll样受体(Toll-like Receptor,TLRs)在识别微生物成分中起着至关重要的作用,包括细菌脂肽(BLPs),它们通过TLR1/2(三酰化BLPs)或TLR2/6(二酰化BLPs)的异源二聚体激活单核细胞,在多种细菌中表达。初步研究表明,尽管TLRs及其相关信号成分表达正常,但在BLP诱导的促炎和Th1极化细胞因子肿瘤坏死因子-α(TNF-α)的合成过程中,人类新生儿单核细胞表现出2-3对数的损伤,但保留了BLP诱导的IL-6的产生,IL-6具有抗炎和Th2极化活性。对表达BLPS的致病细菌E.ColiK1/r的反应中,新生儿肿瘤坏死因子-α的产生也明显受到类似的损害。我们发现,BLP和E.col1诱导的新生儿单核细胞产生的肿瘤坏死因子-α的减少是由于血浆腺苷的作用,腺苷是一种内源性嘌呤代谢产物,具有免疫调节特性,在应激或缺氧条件下从细胞中释放出来。新生儿单个核细胞对腺苷诱导的肿瘤坏死因子-α的产生抑制和腺苷诱导的环磷酸腺苷的产生特别敏感,环磷酸腺苷是一种细胞内代谢物,可以抑制肿瘤坏死因子-α的合成,同时保持IL-6的产生。该项目的总体目标是表征新生儿腺苷系统在调节TLR介导的新生儿单核细胞天然免疫反应中的作用。这一目标将通过三个具体目标来实现:(1)确定新生儿单核细胞对腺苷更敏感的机制,(2)确定腺苷受体亚型(S),该亚型介导抑制BLP和大肠杆菌诱导的新生儿单核细胞产生肿瘤坏死因子-α,以及(3)表征腺苷受体结合导致BLP和E.Coli诱导的单核细胞产生减少的肿瘤坏死因子-α,同时保持IL-6产生的机制。机制分析将定义腺苷如何改变新生儿TLR介导的免疫反应。总体而言,这些研究将加深我们对人类新生儿独特的生理如何从根本上改变出生时的先天免疫的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OFER LEVY其他文献
OFER LEVY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OFER LEVY', 18)}}的其他基金
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
- 批准号:
10435035 - 财政年份:2022
- 资助金额:
$ 36.22万 - 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
- 批准号:
10589826 - 财政年份:2022
- 资助金额:
$ 36.22万 - 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
- 批准号:
10435043 - 财政年份:2022
- 资助金额:
$ 36.22万 - 项目类别:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
- 批准号:
10589800 - 财政年份:2022
- 资助金额:
$ 36.22万 - 项目类别:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
- 批准号:
10435036 - 财政年份:2022
- 资助金额:
$ 36.22万 - 项目类别:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
- 批准号:
10589801 - 财政年份:2022
- 资助金额:
$ 36.22万 - 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
- 批准号:
10290547 - 财政年份:2021
- 资助金额:
$ 36.22万 - 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
- 批准号:
10205742 - 财政年份:2021
- 资助金额:
$ 36.22万 - 项目类别:
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity
新生儿队列发现和验证新生儿疫苗免疫原性的生物标志物
- 批准号:
10323182 - 财政年份:2020
- 资助金额:
$ 36.22万 - 项目类别:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
识别新生儿疫苗免疫原性生物标志物的系统生物学
- 批准号:
10221106 - 财政年份:2020
- 资助金额:
$ 36.22万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 36.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 36.22万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 36.22万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 36.22万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 36.22万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 36.22万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 36.22万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 36.22万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 36.22万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 36.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)